The Interface of Pain and Mood Disturbances in the Rheumatic Diseases
To access this article, please choose from the options below
Dr. Goldenberg is a consultant and on the Advisory Board for Pfizer, Lilly, and Forest Pharmaceuticals.
PII: S0049-0172(08)00213-8
doi:10.1016/j.semarthrit.2008.11.005
© 2010 Elsevier Inc. All rights reserved.
